AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

We’ve gone through blood, sweat, and tears to get here. This validates everything we’ve built,' Saldanha says as Glenmark ...

AbbVie Inc. (NYSE:ABBV) saw its stock jump 3.4% after announcing a major licensing agreement with IGI Therapeutics, securing ...

IGI Therapeutics SA, a wholly-owned subsidiary of Ichnos Glenmark Innovation (IGI)—an alliance between Glenmark Pharma and Ichnos Sciences Inc.—has signed an exclusive licensing agreement with AbbVie ...

The global modified release formulations market is set for continued expansion between 2025 and 2035, with its size projected to rise from USD 282.1 billion to approximately USD 524.7 billion, ...

The Bronchopulmonary Dysplasia Treatment Market is anticipated to be valued at USD 434.1 million in 2025 and is expected to reach USD 788.2 million by 2035, registering a CAGR of 6.1%. The ...

Biopharma company AbbVie will acquire Capstan Therapeutics for up to $2.1 billion in cash, giving it access to promising new ...

The new ARC Healthtech Hub will be led by University of Galway, in partnership with ATU and RCSI University of Medicine and Health Sciences.

Fit-for-Purpose Data for Critical R&D Applications The GDN is purpose-built to solve pharma's most pressing R&D challenges, including: Target and biomarker discovery ...

What factors contribute to India’s lag in R&D spending? Why is R&D central to boosting MSME performance? Rohinton Sidhwa, Partner, Deloitte India, said that R&D boosts innovation and has a remarkable ...